Our Team
Andrew Sternlicht, MD, MA
CEO and Founder
Dr. Sternlicht is an anesthesiologist and former pain management physician with more than 30 years of clinical and research experience. A graduate of the University of Pennsylvania and Yale Medical School, he is currently an Asst. Professor of Anesthesiology at Tufts University Medical Center. Dr. Sternlicht spent over 9 years in pharma and led clinical development and developed intellectual property at several pharmaceutical companies. He was involved in two US drug approvals and developed the initial clinical program and patents for a leading clinical program at Biogen. He previously held senior positions at The Medicines Company, Dyax, and two private companies. He is also the CEO and Founder HHRx Nursing Care Solutions, a 20 year old company in Massachusetts and has 8 US Patents and PCT patents issued or pending.
Consultant Team
Asia is currently using several experienced consultants with decades of pharmaceutical development expertise to help in:
- REGULATORY PROCESSES
- CLINICAL DEVELOPMENT
- CLINICAL OPERATIONS
- MANUFACTURING AND QUALITY
- BUSINESS DEVELOPMENT AND PARTNERING
- LEGAL AND INTELLECTUAL PROPERTY
- MEDICAL SCIENCE AND PRECLINICAL DEVELOPMENT
- INVESTOR RELATIONS
Scientific Advisory Board
Robyn Domsic, MD
Robyn Domsic, MD is an Associate Professor of Medicine and Rheumatology at the University of Pittsburgh. She is the Director of the University of Pittsburgh Scleroderma Clinic. With >15 years of clinical trial experience in developing various therapeutics and clinical trials for scleroderma and Raynaud’s treatment agent, Robyn is an Advisor to the FDA on endpoint development for Rayanud and scleroderma treatment trials and the Chair of our Scientific Advisory Board.
Jerry Molitor, MD, PhD
Jerry Molitor, MD, PhD is a Professor of Medicine and Rheumatology at The University of Minnesota and the Director of the Scleroderma Clinic. He has over 20 years of experience in development and clinical trials for scleroderma and Raynaud’s therapeutics. He has been on the Advisory Boards of multiple large pharma companies for these programs.